Impact of Treatment with Ustekinumab on Severe Infections in a Patient with Uncontrolled Psoriasis and Late-Onset Combined Primary Immunodeficiency: Case Report
Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
PRESTES-CARNEIRO, Luiz Euribel
ABREU, Marilda Aparecida Milanez Morgado de
RONCADA, Eduardo Vinicius Mendes
MUCHON, Diego Garcia
CALIANI, Fernanda Miranda
Citação
PATHOGENS, v.12, n.9, article ID 1156, 8p, 2023
Resumo
A 35-year-old man with a late-onset combined immunodeficiency (LOCID) variant of common variable immunodeficiency, severe plaque psoriasis, psoriatic arthritis, and Crohn's disease was attended in the Regional Hospital of Presidente Prudente and HC-FMUSP, Sao Paulo, Brazil. Anti-IL-12/IL-23 (ustekinumab) monoclonal antibody was prescribed due to the failure of other treatments (phototherapy, oral acitretin) for psoriasis and a Psoriasis Area Severity Index >10. We evaluated the impact of treatment with ustekinumab on severe infectious diseases in a patient with uncontrolled psoriasis and LOCID followed for 8 years. Four quarterly doses of ustekinumab 90 mg and human immunoglobulin replacement (10,000 mg at 28-day intervals) were administered. Immunophenotyping, cultures of lymphocytes, genetic sequencing, and whole exome sequencing were performed to investigate the primary immunodeficiency. Normal lymphocyte proliferation; pathogenic variants in genetic sequencing, and clinically significant variants in the whole exome for primary immunodeficiencies were not detected. The main infections before and after treatment with ustekinumab were chronic sinusitis and gastroenteritis. The patient was infected with COVID-19, dengue (twice) and influenza and was hospitalized three times for intravenous antibiotic therapy. Ustekinumab did not influence the susceptibility of the patient with LOCID to severe infections and significantly improved psoriasis, psoriatic arthritis, and Crohn's disease.
Palavras-chave
late-onset combined immunodeficiency, psoriasis, ustekinumab, infections
Referências
- Bhattacharya Sumona, 2022, Clin Gastroenterol Hepatol, V20, P461, DOI 10.1016/j.cgh.2021.03.039
- Pereira DHB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00862
- Cheng D, 2022, CLIN GASTROENTEROL H, V20, P2366, DOI 10.1016/j.cgh.2022.01.013
- Costa L, 2017, DRUGS R&D, V17, P509, DOI 10.1007/s40268-017-0215-7
- Costagliola G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10204729
- Davidson L, 2022, ACTA DERM-VENEREOL, V102, DOI 10.2340/actadv.v102.175
- Dávila-Seijo P, 2017, J INVEST DERMATOL, V137, P313, DOI 10.1016/j.jid.2016.08.034
- Harris RJ, 2020, FRONTLINE GASTROENTE, V11, P111, DOI 10.1136/flgastro-2019-101237
- Hoffmann JHO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01090
- Jeon C, 2017, HUM VACC IMMUNOTHER, V13, P2247, DOI [10.1080/21645515.2017.1329064, 10.1080/21645515.2017.1356498]
- Lehman H, 2014, CLIN REV ALLERG IMMU, V46, P112, DOI 10.1007/s12016-013-8377-8
- McCusker C, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0290-5
- Miyachi H, 2017, J DERMATOL, V44, pE206, DOI 10.1111/1346-8138.13884
- Penso L, 2021, JAMA DERMATOL, V157, P1056, DOI 10.1001/jamadermatol.2021.2599
- Pescador Ruschel MA., 2023, Statpearls [Internet]
- Prestes-Carneiro LE, 2023, INT J ENVIRON HEAL R, DOI 10.1080/09603123.2023.2199972
- Rabello I.M., 2021, Am. J. Gastroenterol, V116, pS17, DOI [10.14309/01.ajg.0000798856.73091.69, DOI 10.14309/01.AJG.0000798856.73091.69]
- Rizvi FS, 2020, EXPERT REV CLIN IMMU, V16, P1227, DOI 10.1080/1744666X.2021.1850272
- Robert M, 2021, CELL MOL IMMUNOL, V18, P1644, DOI 10.1038/s41423-021-00694-9
- Schuetz C, 2010, AUTOIMMUN REV, V9, P477, DOI 10.1016/j.autrev.2010.02.005
- Velikova T, 2023, ANTIBODIES, V12, DOI 10.3390/antib12010020